The BH3-mimetic venetoclax that blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein and has recently shown great promise in the treatment of patients with relapsed AML including previously difficult to treat subgroups with TP53 alterations [10, 17]. The gene discussed is BCL2; the disease is acute myeloid leukemia.